About Aratana Therapeutics (NASDAQ:PETX)
Aratana Therapeutics, Inc. is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company's portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets. Its lead product candidates in development include small molecules directed at treating osteoarthritis pain and inflammation (AT-001 for dogs, also known as grapiprant for dogs or GALLIPRANT), appetite stimulation (AT-002 for dogs, also known as capromorelin for dogs or ENTYCE) and post-operative pain (AT-003 for dogs, also known as bupivacaine liposome injectable suspension for dogs or NOCITA). AT-001 is a selective antagonist of the prostaglandin E2 (PGE 2) EP4 receptor (EP4 prostaglandin receptor antagonist or EP4 PRA). AT-002 is a potent and selective ghrelin agonist. Its product candidates also include AT-014, AT-016 and AT-018 for dogs.
Industry, Sector and Symbol
Trailing P/E Ratio-3.47881355932203
Forward P/E Ratio-6.64
Sales & Book Value
Annual Sales$25.57 million
Price / Sales7.26
Price / CashN/A
Book Value$1.86 per share
Price / Book2.18
Return on Equity-45.15%
Return on Assets-28.23%
Aratana Therapeutics (NASDAQ:PETX) Frequently Asked Questions
What is Aratana Therapeutics' stock symbol?
Aratana Therapeutics trades on the NASDAQ under the ticker symbol "PETX."
How were Aratana Therapeutics' earnings last quarter?
Aratana Therapeutics Inc (NASDAQ:PETX) announced its earnings results on Tuesday, March, 13th. The biopharmaceutical company reported ($0.19) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.23) by $0.04. The biopharmaceutical company earned $10.46 million during the quarter, compared to analysts' expectations of $5.72 million. Aratana Therapeutics had a negative return on equity of 45.15% and a negative net margin of 185.78%. View Aratana Therapeutics' Earnings History.
When will Aratana Therapeutics make its next earnings announcement?
Where is Aratana Therapeutics' stock going? Where will Aratana Therapeutics' stock price be in 2018?
6 brokers have issued 12-month price targets for Aratana Therapeutics' shares. Their forecasts range from $6.00 to $10.00. On average, they anticipate Aratana Therapeutics' stock price to reach $8.50 in the next year. View Analyst Ratings for Aratana Therapeutics.
What are Wall Street analysts saying about Aratana Therapeutics stock?
Here are some recent quotes from research analysts about Aratana Therapeutics stock:
- 1. According to Zacks Investment Research, "Aratana Therapeutics Inc. is a biopharmaceutical company for animals. The Company is developing compounds for the pet health market, including a non-COXIB analgesic for treating pain, an appetite-stimulating molecule for inappetence and licensed non-opioid local anesthetic for treating post-operative pain. It operates in the United States and Europe. Aratana Therapeutics Inc. is headquartered in Kansas City, Kansas. " (3/7/2018)
- 2. HC Wainwright analysts commented, "Galliprant Approved in EU; Additional Product Approvals Expected in 2018; Reiterate Buy Galliprant approved for canine osteoarthritis in Europe. On January 11, Aratana announced that the EMA has granted Galliprant marketing approval for the treatment of pain associated with mild to moderate osteoarthritis in dogs. Galliprant is licensed to Elanco, the animal health division of Eli Lilly (LLY; not rated), who has exclusive rights to commercialize the drug globally. Galliprant was first approved in the US in March 2016, and in the nine months ended September 30, 2017, generated approximately $9M in product sales and $4M in license and collaboration revenue for Aratana. Going forward, Elanco has assumed all development, regulatory and manufacturing responsibilities for Galliprant, and we expect the company to launch the drug in Europe in 2Q18." (1/16/2018)
Who are some of Aratana Therapeutics' key competitors?
Some companies that are related to Aratana Therapeutics include Dermira (DERM), Strongbridge Biopharma (SBBP), Albireo Pharma (ALBO), Arsanis (ASNS), Seres Therapeutics (MCRB), AVEO Pharmaceuticals (AVEO), Celyad (CYAD), Merus (MRUS), Syndax Pharmaceuticals (SNDX), Celldex Therapeutics (CLDX), Kadmon (KDMN), Adverum Biotechnologies (ADVM), Aquinox Pharmaceuticals (AQXP), Catalyst Biosciences (CBIO), DURECT (DRRX), NicOx (NICXF), Cellular Biomedicine Group (CBMG) and Osiris Therapeutics (OSIR).
Who are Aratana Therapeutics' key executives?
Aratana Therapeutics' management team includes the folowing people:
- Wendy L. Yarno, Chairman of the Board (Age 63)
- Steven St. Peter M.D., President, Chief Executive Officer, Director (Age 49)
- Craig A. Tooman, Chief Financial Officer, Treasurer (Age 49)
- Brent Standridge, Chief Operating Officer (Age 58)
- Ernst Heinen Ph.D., Chief Development Officer (Age 52)
- Laura A. Brege, Independent Director (Age 59)
- David L. Brinkley, Independent Director (Age 57)
- Robert Benthall Gerber Jr., Independent Director (Age 52)
- Irvine O. Hockaday Jr. Esq., Independent Director (Age 81)
- Merilee Raines, Independent Director (Age 61)
Has Aratana Therapeutics been receiving favorable news coverage?
News coverage about PETX stock has trended somewhat positive recently, according to Accern Sentiment Analysis. The research firm scores the sentiment of press coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Aratana Therapeutics earned a news sentiment score of 0.06 on Accern's scale. They also assigned news coverage about the biopharmaceutical company an impact score of 44.85 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.
Who are Aratana Therapeutics' major shareholders?
Aratana Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional investors include Franklin Resources Inc. (13.81%), Broadfin Capital LLC (9.99%), BlackRock Inc. (7.13%), AWM Investment Company Inc. (3.44%), General American Investors Co. Inc. (2.60%) and Millennium Management LLC (1.44%). Company insiders that own Aratana Therapeutics stock include Brent Standridge, Craig A Tooman, Ernst Heinen, Healthcare Master Fun Broadfin, Julia A Stephanus and Peter Steven St. View Institutional Ownership Trends for Aratana Therapeutics.
Which major investors are selling Aratana Therapeutics stock?
PETX stock was sold by a variety of institutional investors in the last quarter, including Broadfin Capital LLC, Franklin Resources Inc., AWM Investment Company Inc., BlackRock Inc., TIAA CREF Investment Management LLC and Mariner Wealth Advisors LLC. Company insiders that have sold Aratana Therapeutics company stock in the last year include Brent Standridge, Craig A Tooman, Ernst Heinen, Healthcare Master Fun Broadfin and Peter Steven St. View Insider Buying and Selling for Aratana Therapeutics.
Which major investors are buying Aratana Therapeutics stock?
PETX stock was purchased by a variety of institutional investors in the last quarter, including Millennium Management LLC, General American Investors Co. Inc., Wells Fargo & Company MN, Granite Investment Partners LLC, Ellington Management Group LLC, Deutsche Bank AG, Renaissance Technologies LLC and Sheaff Brock Investment Advisors LLC. View Insider Buying and Selling for Aratana Therapeutics.
How do I buy shares of Aratana Therapeutics?
Shares of PETX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Aratana Therapeutics' stock price today?
One share of PETX stock can currently be purchased for approximately $4.05.
How big of a company is Aratana Therapeutics?
Aratana Therapeutics has a market capitalization of $192.13 million and generates $25.57 million in revenue each year. The biopharmaceutical company earns $-47,510,000.00 in net income (profit) each year or ($1.18) on an earnings per share basis. Aratana Therapeutics employs 85 workers across the globe.
How can I contact Aratana Therapeutics?
Aratana Therapeutics' mailing address is 11400 TOMAHAWK CREEK PARKWAY SUITE 340, LEAWOOD KS, 66211. The biopharmaceutical company can be reached via phone at 913-353-1000 or via email at [email protected]
MarketBeat Community Rating for Aratana Therapeutics (PETX)MarketBeat's community ratings are surveys of what our community members think about Aratana Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Aratana Therapeutics (NASDAQ:PETX) Analysts' Consensus Rating (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Today||30 Days Ago||90 Days Ago||180 Days Ago|
|Consensus Rating: ||Buy||Buy||Buy||Buy|
|Consensus Rating Score: ||2.83||2.60||2.80||3.00|
|Ratings Breakdown: ||0 Sell Rating(s)|
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
2 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
|Consensus Price Target: ||$8.50||$8.75||$8.75||$8.33|
|Price Target Upside: ||109.88% upside||67.62% upside||62.64% upside||55.18% upside|
Aratana Therapeutics (NASDAQ:PETX) Consensus Price Target History
Aratana Therapeutics (NASDAQ:PETX) Analyst Ratings History
(Data available from 3/23/2016 forward)
Aratana Therapeutics (NASDAQ:PETX) Earnings History and Estimates Chart
Aratana Therapeutics (NASDAQ PETX) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|3/13/2018||Q4 2017||($0.23)||($0.19)||$5.72 million||$10.46 million||View||N/A|
|11/2/2017||Q3 2017||($0.24)||($0.21)||$6.47 million||$6.16 million||View||N/A|
|8/3/2017||Q2 2017||($0.29)||($0.26)||$4.50 million||$5.16 million||View||Listen|
|5/8/2017||Q1 2017||($0.34)||($0.34)||$3.05 million||$3.80 million||View||Listen|
|3/13/2017||Q4 2016||($0.42)||($0.64)||$0.80 million||$0.29 million||View||N/A|
|11/3/2016||Q316||($0.48)||($0.38)||$0.13 million||$0.04 million||View||N/A|
|8/4/2016||Q216||$0.24||$0.61||$15.14 million||$38.05 million||View||N/A|
|5/5/2016||Q116||($0.42)||($0.52)||$0.13 million||$0.17 million||View||N/A|
|3/14/2016||Q415||($0.41)||($0.37)||$0.21 million||$0.06 million||View||N/A|
|11/5/2015||Q315||($0.39)||($1.58)||$0.21 million||$0.23 million||View||N/A|
|8/6/2015||Q2||($0.38)||($0.23)||$0.18 million||$0.23 million||View||N/A|
|5/7/2015||($0.40)||($0.26)||$0.30 million||$0.16 million||View||N/A|
|3/12/2015||Q315||($0.35)||($0.30)||$0.10 million||$0.25 million||View||N/A|
|11/10/2014||Q315||($0.41)||($0.35)||$0.25 million||$0.43 million||View||N/A|
|8/12/2014||Q215||($0.36)||($0.32)||$0.14 million||$0.30 million||View||N/A|
|5/13/2014||Q115||($0.35)||($0.34)||$0.09 million||$0.18 million||View||N/A|
Aratana Therapeutics (NASDAQ:PETX) Earnings Estimates
2018 EPS Consensus Estimate: ($0.57)
2019 EPS Consensus Estimate: $0.07
(Earnings estimates data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Aratana Therapeutics (NASDAQ:PETX)
No dividend announcements for this company have been tracked by MarketBeat.com
Aratana Therapeutics (NASDAQ PETX) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 5.20%
Institutional Ownership Percentage: 71.07%
Aratana Therapeutics (NASDAQ PETX) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|1/30/2018||Peter Steven St||CEO||Sell||19,367||$4.77||$92,380.59||672,259|| |
|1/11/2018||Craig A Tooman||Insider||Sell||30,000||$5.27||$158,100.00||75,024|| |
|12/1/2017||Healthcare Master Fun Broadfin||Major Shareholder||Sell||890,516||$5.70||$5,075,941.20|| |
|11/29/2017||Healthcare Master Fun Broadfin||Major Shareholder||Sell||116,516||$6.53||$760,849.48|| |
|11/10/2017||Peter Steven St||Insider||Sell||50,000||$7.00||$350,000.00||529,359|| |
|10/2/2017||Peter Steven St||Insider||Sell||50,000||$6.24||$312,000.00|| |
|9/25/2017||Brent Standridge||COO||Sell||10,000||$6.11||$61,100.00||70,267|| |
|9/15/2017||Ernst Heinen||Insider||Sell||10,000||$6.25||$62,500.00||130,994|| |
|4/17/2017||Peter Steven St||Insider||Sell||50,000||$5.54||$277,000.00||582,693|| |
|1/27/2017||Peter Steven St||Insider||Sell||50,000||$7.72||$386,000.00||632,693|| |
|12/15/2016||Peter Steven St||Insider||Sell||50,000||$7.63||$381,500.00||592,793|| |
|10/3/2016||Ernst Heinen||Insider||Sell||10,000||$10.00||$100,000.00||115,494|| |
|9/9/2016||Craig A Tooman||Insider||Sell||30,000||$9.25||$277,500.00||72,424|| |
|8/9/2016||Peter Steven St||Insider||Sell||50,000||$9.25||$462,500.00||642,793|| |
|6/28/2016||Julia A Stephanus||Insider||Sell||30,000||$6.25||$187,500.00||127,503|| |
|6/17/2016||Peter Steven St||CEO||Sell||100,000||$6.26||$626,000.00||717,793|| |
|6/10/2016||Ernst Heinen||Insider||Sell||15,000||$6.72||$100,800.00||125,494|| |
|2/1/2016||Craig A Tooman||CFO||Sell||2,806||$3.36||$9,428.16||102,424|| |
|11/9/2015||Craig A Tooman||CFO||Sell||3,620||$7.52||$27,222.40||69,980|| |
|10/2/2015||Craig A Tooman||CFO||Sell||3,250||$8.06||$26,195.00||73,600|| |
|7/15/2015||Ernst Heinen||Insider||Sell||15,000||$17.06||$255,900.00|| |
|4/27/2015||Linda Rhodes||Insider||Sell||15,000||$15.00||$225,000.00|| |
|3/6/2015||Linda Rhodes||Insider||Sell||20,000||$20.00||$400,000.00|| |
|3/6/2015||Vort John Vander||Director||Sell||6,137||$20.01||$122,801.37|| |
|1/13/2015||Julia A Stephanus||Insider||Sell||6,300||$19.00||$119,700.00|| |
|1/13/2015||Peter Steven St||CEO||Sell||75,000||$19.23||$1,442,250.00|| |
|12/22/2014||Linda Rhodes||Insider||Sell||10,000||$18.00||$180,000.00|| |
|7/3/2014||Julia A Stephanus||Insider||Sell||2,000||$17.33||$34,660.00|| |
|7/1/2014||Linda Rhodes||Insider||Sell||10,000||$16.00||$160,000.00|| |
|6/17/2014||Linda Rhodes||Insider||Sell||4,626||$15.00||$69,390.00|| |
|6/16/2014||Julia A Stephanus||Insider||Sell||8,000||$13.90||$111,200.00|| |
|6/2/2014||Peter Steven St||CEO||Sell||25,000||$13.47||$336,750.00|| |
|5/5/2014||Ernst Heinen||Insider||Sell||10,000||$13.42||$134,200.00||95,294|| |
|2/3/2014||Ronald Meeusen||Director||Sell||500,000||$19.00||$9,500,000.00|| |
|7/2/2013||Julia A Stephanus||Insider||Buy||2,000||$6.00||$12,000.00|| |
|7/2/2013||Peter Steven St||CEO||Buy||8,333||$6.00||$49,998.00|| |
|7/2/2013||Ventures Ix L.P. Avalon||Major Shareholder||Buy||500,000||$6.00||$3,000,000.00|| |
Aratana Therapeutics (NASDAQ PETX) News Headlines
Aratana Therapeutics (NASDAQ:PETX) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Aratana Therapeutics (NASDAQ:PETX) Income Statement, Balance Sheet and Cash Flow Statement
Aratana Therapeutics (NASDAQ PETX) Stock Chart for Friday, March, 23, 2018